Twist Bioscience reported its fiscal 2024 fourth quarter financial results, surpassing expectations with revenues of $84.71 million, a 27% increase from the previous year. The company recorded a loss of 59 cents per share, which was better than analysts' predictions of a 69-cent loss. Despite the positive revenue news, shares of Twist Bioscience fell 5.3% to $36.89 prior to the earnings announcement. In addition, the CFO clarified that related party revenue for fiscal 2024 totaled $12 million, not just for the fourth quarter. Other companies reporting their third quarter results include Sensus Healthcare, Cellectar Biosciences, Immatics, Actinium Pharmaceuticals, and Vaccinex, all of which provided updates alongside their financial disclosures.